

LITERATURA

1. Allison MA, Manson JE, Langer RD. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. *Menopause*. 2008;15(4 Pt 1):639–47.
2. Almeida OP, Lautenschlager NT, Vasikaran S et al. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older. Effect on mood, cognition and quality of life. *Neurobiology of aging*. 2006;27(1):141–9.
3. Archer DF, Baber RJ, Barlow D, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. *Climacteric*. 2011;14(3):302–20.
4. Baracat EC, Barbosa IC, Giordano MG, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. *Climacteric*. 2002;5(1):60–9.
5. Barnes JF, Farish E, Rankin M, et al. A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors. *Atherosclerosis*. 2002;160(1):185–93.
6. Barr RG, Camargo CA Jr. HRT and obstructive airway disease. *Treat Respir Med*. 2004;3 (1):1–7.
7. Barr RG, Wentowski CC, Grodstein F, et al. Prospective study of postmenopausal hormone use and newly diagnosed asthma chronic obstructive pulmonary disease. *Arch Intern Med*. 2004; 164(4):379–86.
8. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. *Annu Rev Public Health*. 1998; 19:55–72.
9. Battaglia C, Mancini F, Regnani G, et al. Hormone therapy and ophthalmic artery blood flow changes in women with primary open-angle glaucoma. *Menopause*. 2004;11(1):69–77.
10. Behnia-Willison F, Sarraf S, Miller J et al. Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause. *Eur J Obstet Gynecol Reprod Biol*. 2017;213:39–44.
11. Benitez del Catillo JM, del Rio T, Garcia-Sanchez J. Effects of estrogen use on lens transmittance in postmenopausal women. *Ophthalmology*. 1997;104(6):970–3.
12. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. *Lancet*. 2002;360(9337):942–4.
13. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. *Lancet*. 2002;360:942–4.
14. Bergeron C, Nogales FF, Rechberger T, et al. Ultra low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-

- oestradiol and 2.5 mg dydrogesterone: protection of the endometrium and amenorrhoea rate. *Maturitas*. 2010;66(2):201–5.
15. Birkhauser MH, Panay N, Archer DF, et al. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. *Climacteric*. 2008;11(2):108–23.
 16. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. *Lancet*. 1997;350(9084):1047–59.
 17. Broulík P. Kostní onemocnění ve stáří – metabolické osteopatie. In: Kalvach Z, Zadák Z, Jirák R, et al. *Geriatric a gerontologie*. Praha: Grada; 2004: p. 626–44.
 18. Busch TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. *Circulation*. 1987;75(6):1102–9
 19. Cagnacci A, Mallus E, Tuveri F, et al. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. *J Clin Endocrinol Metab*. 1997; 82(1):251–3.
 20. Calle CE, Mirakle-McMahill H, Thun M, et al. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. *J Nat Canc Instit*. 1995;87(7):517–23.
 21. Campbell JA, Douglas JG, Francis RM, et al. HRT or etidronate for osteoporosis in postmenopausal asthmatics on glucocorticoids: a randomised factorial trial. *Scott Med J*. 2009; 54(1):21–5.
 22. Cardozo L, Bachmann G, McGlish D, et al. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. *Obstet Gynecol*. 1998;92(4 Pt 2):722–7.
 23. Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women – a double-blind placebo-controlled study. *J Obstet Gynaecol*. 2001;21(4):383–5.
 24. Cirillo DJ, Wallace RB, Wu L, et al. Effect of hormone therapy on risk of hip and knee joint replacement in the WHI. *Arthritis Rheum*. 2006;54(10):3194–204.
 25. Clarke S, Kelleher J, Lloyd-Jones H, et al.: A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. *BJOG*. 2002;109(9):1056–62.
 26. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. *J Clin Endocrinol Metab*. 2001;86(11):5396–404.
 27. Coelingh Bennink HJT, Heegaard AM, Visser M, et al. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. *Climacteric*. 2008;11 Suppl 1:2–14.
 28. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. *N Engl J Med*. 1987;316(18):1105–10.
 29. Collins LC, Peiris A. Bronchospasm secondary to estrogen replacement therapy. *Chest*. 1993; 104(4):1300–2.

30. Collins P, Rosano G, Casey C, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. *Eur Heart J.* 2007; 28(16): 2028–40.
31. Collins R, Beale CM. The cardioprotective role of HRT – a clinical update. London: Partheon Publishing; 1996.
32. Craig MC, Maki PM, Murphy DG. The WHIMS: findings and implications for treatment. *Lancet Neurol.* 2005;4(3):190–4.
33. Cszimadi I, Collet JP, Benedett A, et al. The effects of transdermal and oral oestrogen replacement therapy on colorectal cancer risk in postmenopausal women. *Br J Cancer.* 2004;12;90(1):76–81.
34. Cumming RG, Mitchell P. Hormone replacement therapy, reproductive factors, and cataract. The Blue Mountains Eye Study. *Am J Epidemiol.* 1997;145(3):242–9.
35. Cushman M, Legault C, Barret-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. *Circulation.* 1999;100(7):717–22.
36. Cutner A, Cardozo LD, Benness CJ. Assessment of urinary symptoms in early pregnancy. *Br J Obstet Gynaecol.* 1991;98(12):1283–6.
37. Čepický P, Bendová M, Burdová M, et al. Doporučení k hormonální terapii a substituci perimenopauzy a postmenopauzy. Aktualizace 2005. *Čes Gynek.* 2006;71(2):150–2.
38. Češka R. Cholesterol a ateroskleróza: Léčba hyperlipidemií. Praha: Maxdorf; 1999.
39. Daly E, Vessey MP, Hawkins MC et al. Risk of venous thromboembolism in users of HRT. *Lancet.* 1996;348:977–80.
40. Davis FG, Furmer SZ, Persky V et al. The influence of parity and exogenous female hormones on risk of colorectal cancer. *Int J Cancer.* 1989;43:587–90.
41. Davis SR. The effect of tibolone on mood and libido. *Menopause.* 2002;9(3):162–70.
42. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. *J Clin Endocrinol Metab.* 2003; 88(6):2470–8.
43. de Kleijn MJ, Wilink HW, Bots ML, et al. Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women. *Atherosclerosis.* 2001;159(2):357–65.
44. Defay R, Pinchinat S, Lumbroso S, et al. Sex steroids and age-related macular degeneration in older French women: the POLA study. *Ann Epidemiol.* 2004;14(3):202–8.
45. Delaney MF. Strategies for prevention and treatment of osteoporosis during early postmenopause. *Am J Obstet Gynecol.* 2006;194(2 Suppl):S12–23.
46. Dennison EM, Arden NK, Kellingray S, et al. Hormone replacement therapy, other reproductive variables and symptomatic hip osteoarthritis in elderly white women: a case-control study. *Br J Rheumatol.* 1998;37(11):1198–202.
47. DiCarlo C, Tommaselli GA, Sammartino A, et al. Serum leptin levels and body composition in postmenopausal women. *Menopause.* 2004;11(4):466–73.

48. Donát J. Postmenopauza. Hradec Králové: Domena; 2003.
49. Dugal R, Hesla K, Soerdal T, et al. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. *Acta Obstet Gynecol Scand.* 2000; 79(4):293–7.
50. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA.* 2004;291(14):1701–12.
51. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. *JAMA.* 1995;273(3):199–208.
52. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. *JAMA.* 1996;276(17):1389–96.
53. Egarter C, Sator M, Berghammer P, et al. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. *Int J Gynaecol Obstet.* 1999;64(3):281–6.
54. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double blind placebo controlled study. *Eur J Obstet Gynecol Reprod Biol.* 1992;44(2):137–44.
55. Ettinger B, Genant HK, Steiger P, et al. Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. *Am J Obstet Gynecol.* 1992;166(2):479–88.
56. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. *Climacteric.* 2010;13(3):219–27.
57. Fait T, Donát J, Jeniček J, et al. Doporučení pro hormonální substituční terapii v postmenopauze. *Čes Gynek.* 2010;75(2):109–10.
58. Fait T, Vrablík M, Cibula D, et al. Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study. *Neuro Endocrinol Lett.* 2006;27(5):665–8.
59. Fait T, Vrablík M, Zizka Z, Kostirova M. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study. *Gynecol Obstet Invest.* 2008;65(1):47–51.
60. Fait T. Teorie terapeutického okna pro hormonální terapii a ischemickou chorobu srdeční potvrzena. *Klim Med.* 2012;17(4):7–9.
61. Fantl JA et al. Efficacy of estrogen supplementation in the treatment of urinary incontinence. *Obstet Gynecol.* 1996;88:745–9.
62. Farish E, Barnes JF, Fletcher CD, et al. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen. *Menopause.* 1999;6(2):98–104.
63. Fernandez E, Bosetti C, La Vecchia C, et al. Sex differences in colorectal cancer mortality in Europe 1955–1996. *Eur J Cancer Prev.* 2000;9(2):99–104.
64. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. *J Am Med Assoc.* 2002;288(3):366–8.
65. Forbes L. Do estrogens and progesterone influence asthma? *Thorax.* 1999;54(3):265–7.
66. Fournier A et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat.* 2008a;107:103–11.

67. Fournier A et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. *J Clin Oncol*. 2008b;26:1260–8.
68. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. *Circulation*. 2002;105(8):917–22.
69. Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. *Maturitas*. 2008;59(1):2–6.
70. Gambacciani M, Ciaponi M, Cappagli B, et al. Climacteric modification in body weight and fat tissue distribution. *Climacteric*. 1999;2(1):37–44.
71. Genazzani AR, Gambacciani M. A personal initiative for women's health: to challenge the Women's Health Initiative. *Gynecol Endocrinol*. 2002;16(4):255–7.
72. Genazzani AR, Petraglia F, Facchinetti F, Genazzani AD, Bergamaschi M, Grasso A, Volpe A. Effects of Org OD 14 on pituitary and peripheral beta-endorphin in castrated rats and post-menopausal women. *Maturitas*. 1987;Suppl 1:35–48.
73. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. *Fertil Steril*. 2001;75(5):898–915.
74. Gómez Real F, Svanes C, Björnsson EH, et al. Hormone replacement therapy, body mass index and asthma in perimenopausal women: a cross sectional survey. *Thorax*. 2006;61(1):34–40.
75. Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease. The Framingham study. *Ann Intern Med*. 1978;89(2):157–61.
76. Grady D, Herrington D, Bittner V. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *JAMA*. 2002;288(1):49–57.
77. Grady D, Wenger NK, Herrington D et al. Postmenopausal HT increase risk for venous thromboembolic diseases. *Annals Int Med*. 2000;132(9):689–96.
78. Greendale GA, Espeland M, Sloane S., et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. *Arch Intern Med*. 2002; 162(6):665–72.
79. Grodstein F, Colditz GA, Stampfer MJ. Post-menopausal hormone use and tooth loss: a prospective study. *J Am Dent Assoc*. 1996;127(3):370–7.
80. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. *N Engl J Med*. 1996;335(7):453–61.
81. Grodstein F. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. *N Engl J Med*. 1996;335(7):453–61.
82. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. *J Womens Health (Larchmt)*. 2006;15(1):35–44.
83. Gruchow HW, Anderson AJ, Barboriah JJ, Sulocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. *Am Heart J*. 1988;115(5):954–63.

84. Gurrpide E, Schwers J, Welch MT, et al. Fetal and maternal metabolism of estradiol during pregnancy. *J Clin Endocrinol Metab.* 1966;26(12):1355–65.
85. Haarbo J. Postmenopausal HRT prevents central distribution of body fat after menopause. *Metabolism.* 1991;40(12):1323–6.
86. Haggerty CL, Ness RB, Kelsey S, Waterer GW. The impact of estrogen and progesteron on asthma. *Ann Allergy Asthma Immunol.* 2003;90(3):284–91;quiz 291–3, 347.
87. Hales AM, Chamberlain JG, Murphy CR et al. Estrogen protects against cataract induced by TGFbeta. *J Exp Med.* 1997;185:273–80.
88. Hammar M, Christau S, Nathorst-Boos J, et al. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. *Br J Obstet Gynaecol.* 1998;105(8):904–11.
89. Hammond GL, Hogeween KN, Visser M, Coelingh Bennink HJT. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. *Climacteric.* 2008;11 Suppl 1:41–6.
90. Harding JJ. Estrogens and cataract (letter). *Arch Ophthalmol.* 1994;112:1511.
91. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: adressing the unfinished agenda of staging reproductive aging. *Menopause.* 2012;19(4): 387–95.
92. Heikkinen J, Vaheri R, Kainulainen P, et al. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high – and low-dose estrogen-progestin regimens. *Osteoporos Int.* 2000;11(11):929–37.
93. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. *JAMA.* 2008;299:1036–45.
94. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. *Arch Intern Med.* 1991; 151(1):75–8.
95. Hickman TN, Nammoun AB, Hinton EL et al. Timing of ERT following hysterectomy with oophorectomy for endometriosis, *Obstet Gynecol.* 1998;91,673–7.
96. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart dinase prevention with hormone therapy: past, present and future perspective. *Climacteric.* 2012;15(3):217–28.
97. Hodis HN, Mack WJ. Atherosclerosis imaging methods: assessing cardiovascular disease and evaluating the role of estrogen in the prevention of atherosclerosis. *Am J Cardiol.* 2002;89(12A):19E–27E;-discussion 27E.
98. Høibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy – results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). *Thromb Haemost.* 2000;84(6):961–7.
99. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. *BJOG.* 2002;109(8):886–93.

100. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. *JAMA*. 1998; 280(7):605–13.
101. Hundrup YA, Ekholm O, Hoidrup S, et al. Risk factors for hip fracture and a possible effect modification by HRT. The Danish Nurse Cohort Study. *Eur J Epidemiol*. 2005; 20(10):871–7.
102. Chlebowski RT, Waclavski-Vende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. *N Engl J Med*. 2004;350(10):991–1004.
103. Ingelman-Sundberg A et al. Cytosol oestrogens receptors in urogenital tissues in stress incontinent women. *Acta Obstet Gyn*. 1981; 60:585–6.
104. Jackson RD, LaCroix AZ, Grass M, et al. Calcium and vitamin D supplementation and the risk of fractures. *N Engl J Med*. 2006; 354(7):669–83.
105. Jackson S, Shepherd A, Brookes S, Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind placebo-controlled trial. *Br J Obstet Gynaecol*. 1999;106(7):711–8.
106. Jacobs EJ, White E, Weiss NS. Exogenous hormones, reproductive history and colon cancer. *Cancer Causes and Control*. 1994;5:359–66.
107. Jarvis D, Leynaert B. The association of asthma, atopy and lung function with HRT and surgical cessation of menstruation in a population-based sample of English women. *Allergy*. 2008;63(1):95–102.
108. Jeníček J. Hormonální substituční terapie a klimakterium. Praha: Grada; 2001.
109. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. *Arch Intern Med*. 1999;159(11):1215–20.
110. Kahn HA, Leibowitz HM, Gynley J., et al. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. *Am J Epidemiol*. 1977;106(1):33–41.
111. Kanis JA, McCloskey EV, Johansson H, et al. European Guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 2013;24:23–57.
112. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. *Maturitas*. 2005;51(1):21–8.
113. Kessel B, Nachtigall L, Plouffe L, et al. Effect of raloxifene on sexual function in postmenopausal women. *Climacteric*. 2003;6(3):248–56.
114. Koh KK, Ahn JY, Jin DK, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. *Arterioscler Thromb Vasc Biol*. 2003;23(10):1889–94.
115. Kos-Kudla B, Ostrowska Z, Marek B, et al. Effects of hormone replacement therapy on endocrine and spirometric parameters in asthmatic postmenopausal women. *Gynecol Endocrinol*. 2001;15(4):304–11.
116. Kundu N, Wachs M, Iverson GB, Petersen LP. Comparison of serum unconjugated estriol and estetrol in normal and complicated pregnancies. *Obstet Gynecol*. 1981;58(3):276–81.

117. Landgren MB, Coelingh Bennink HJT, Helmond FA, et al. Dose-response analysis of effect of tibolone on climacteric symptoms. *BJOG*. 2002;109(10):1109–14.
118. Lange P, Parner J, Prescott E, et al. Exogenous female sex steroid hormones and risk of asthma and asthma-like symptoms: a cross sectional study of the general population. *Thorax*. 2001;56(8):613–6.
119. Lee E, Wutoh AK, Xue Z, et al. Osteoporosis management in a Medicaid population after the Women's Health Initiative study. *J Womens Health (Larchmt)*. 2006;15(2):155–61.
120. Leske MC, Wu S-Y, Connell AMS, et al. Lens opacities, demographic factors and nutritional supplements in the Barbados Eye Study. *Int J Epidemiol*. 1997;26(6):1314–22.
121. Lieberman D, Kopernik G, Porath A, et al. Sub-clinical worsening of bronchial asthma during estrogen replacement therapy in asthmatic post-menopausal women. *Maturitas*. 1995;21(2):153–7.
122. Lindsay PC, Shaw RW, Coeling Bennink HJ, et al. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). *Fertil Steril*. 1996;65(2):342–8.
123. Lindsay R, Gallagher JC, Kleerekoper M, et al. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. *JAMA*. 2002;287(20):2668–76.
124. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. *Lancet*. 1976;1(7968):1038–41.
125. Lloyd GW, Patel NR, McGing EA, et al. Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina. *Int J Clin Pract*. 1998; 52(3):155–7.
126. Lobo RA, Kelsey J, Marcus R. *Menopause. Biology and Pathobiology*. London: Academic Press; 2000.
127. Lundström E, Bygdesson M, Svane G, et al. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. *Climacteric*. 2007;10(3):249–56.
128. Lunniss PJ, Mann CV. Classification of internal haemorrhoids: a discussion paper. *Colorectal Dis*. 2004;6(4):226–32.
129. Lyytinen H et al. Finish Cohort Study. *Obst Gyn*. 2009;113:65–73.
130. MacQueen G, Born L, Steiner M. The SSRI sertraline: its profile and use in psychiatric disorders. *CNS Drug Rev* 2001;7(1):1–24.
131. Manson JE. The Kronos Early Estrogen Prevention Study by Charlotte Barker. *Womens Health (Lond Engl)*. 2013;9(1):9–11.
132. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, et al.; Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. *Diabetologia*. 2004;47(7):1175–87.
133. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev*. 2012 Jul 11;7:CD004143.
134. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ*. 1996;312(7041):1254–9.

135. Mayers JR, Sherman CB. Should supplemental estrogens be used as steroid sparing agents in asthmatic women? *Chest*. 1994;106(1):318–9.
136. McClung M et al. *Bone*. 1998;23(5):(Suppl):S465.
137. Meeuwse IB, Samson MM, Duursma SA, et al. The influence of tibolone on quality of life in postmenopausal women. *Maturitas*. 2002;41(1):35–43.
138. Meier CR, Sturkenboom MC, Cohen AS, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. *J Rheumatol*. 1998; 25(8):1515–9.
139. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. *Circulation*. 2001;104(19):2256–9.
140. Mendelson MT, Moglioretti D, Newcomb PA et al. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. *Cancer Causes and Control*. 2003;14:979–84.
141. Mendelson MT, Moglioretti D, Newcomb PA, et al. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. *Cancer Causes Control*. 2003;14(10):979–84
142. Mendoza N, Pison JA, Fernandez M, et al. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. *Maturitas*. 2002;41(4):289–98.
143. Mettler L, Olsen PG. Long term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. *Maturitas*. 1991;14(1):23–31.
144. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and the cardiovascular and all-cause mortality. *Menopause*. 2015;22:976–83
145. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. *J Clin Endocrinol Metab*. 2015;100:4588–94.
146. Milewicz A, Tworowska U, Demissie M. Menopausal obesity – myth or fact? *Climacteric*. 2001;4(4):273–83.
147. Modugno F, Ness RB, Ewing S, et al. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. *Obstet Gynecol*. 2003;101(2):353–61.
148. Moriss EP, Wilson PO, Robinson J, et al. Long term effects of tibolone on the genital tract in postmenopausal women. *Br J Obstet Gynaecol*. 1999;106(9):954–9.
149. Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. *Climacteric*. 2012;15 Suppl 1:11–7.
150. Nanda K, Bastian LA, Hasselblad V, Simmel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. *Obstet Gynecol*. 1999;93(5 Pt 2):880–8.
151. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights Views & Attitudes (VIVA) – results from an international survey. *Climacteric*. 2012 15:36–44.
152. Nappi RE, Mattsson LA, Lachowsky M, et al. The CLOSER survey: Impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. *Maturitas*. 2013;75(4):373–9.
153. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic

- review to update the U.S. Preventive Services Task Force recommendations. *Ann Intern Med.* 2012;57(2):104–13.
154. Nevitt MC, Cummings SR, Lane NE, et al. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. *Arch Intern Med.* 1996;156(18):2073–80.
 155. Nevitt MC, Felson DT, Williams EN, Grady D. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2001;44(4):811–8.
 156. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. *J National Cancer Institute.* 1995;87(14):1067–71.
 157. Newton KM, LaCroix AZ, McKnight B, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. *Am J Epidemiol.* 1997;145(3):269–77.
 158. Newton KM. Estrogen replacement therapy and prognosis after first myocardial infarction. *Am J Epidemiol.* 1997;145(3):269–77.
 159. Nikader E, Rutanen EM, Nieminen P, et al. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. *Fertil Steril.* 2005; 83(1):137–42.
 160. Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17beta-estradiol dose for treating vasomotor symptoms. *Obstet Gynecol.* 2000;95(5):726–31.
 161. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. *J Bone Miner Res.* 1996;11(8):1043–51.
 162. Paganini-Hill A. Estrogen replacement therapy and colorectal cancer risk in elderly women. *Dis Colon Rectum.* 1999;42(10):1300–5.
 163. Palomba S, Affinito P, Di Carlo C, et al. Long-term administration of tibolone plus gonadotropin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profiles. *Fertil Steril.* 1999;72(5):889–95.
 164. Panay N, Ylikorkala O, Archer DF, et al. Ultra-low-dose estradiol and norethisteron acetate: effective menopausal symptom relief. *Climacteric.* 2007;10(2):120–31.
 165. Panotopoulos G, Ruiz J-Ch, Raison J, et al. Menopause, fat and lean distribution in obese women. *Maturitas.* 1996; 25(1):11–9.
 166. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation.* 2000;102(18):2165–8.
 167. Peipins LA, Newman B, Snadler RS. Reproductive history, use of exogenous hormones and risk of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev.* 1997;6:671–5.
 168. POI Guideline Development Group: Management of women with premature ovarian insufficiency. *ESHRE*; 2015. p. 1–24.
 169. Postma DS. Gender differences in asthma development and progression. *Gend Med.* 2007;4 Suppl B:S133–46.
 170. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. *Cancer Epidemiol Biomarkers Prev.* 1996;5(10):779–84.

171. Prelevic GM, Beljic T, Balint-Peric L, et al. Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus. *Maturitas*. 1998;28(3):271–76.
172. Quigley ME, Martin PL, Burnier AM, Brooks P. Estrogen therapy arrest bone loss in elderly women. *Am J Obstet Gynecol*. 1987;156(6):1516–23.
173. Rasgon LN, Dunkin J, Fairbanks L, et al. Estrogen and response to sertraline in postmenopausal women with major depressive disorder. *J Psych Res* 2007;41:338–43.
174. Recker RR, Davies KM, Dowd RM, et al. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. *Ann Intern Med*. 1999;130(11):897–904.
175. Reginster JY, Kvasz A, Bruyere O, Henrotin Y. Is there any rationale for prescribing hormone replacement therapy (HRT) to prevent or to treat osteoarthritis? *Osteoarthritis Cartilage*. 2003; 11(2):87–91.
176. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med*. 2000;342(12):836–43.
177. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. *Circulation*. 2001;103(13):1813–8.
178. Rigg LA. Estrogen replacement therapy for atrophic vaginitis. *Int J Fertil*. 1986;31(3 Suppl [ESTROGEN]):29–34.
179. Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. *Joint Bone Spine*. 2003;70(4):257–62.
180. Rioux JE, Devlin C, Gelfand MM, et al. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. *Menopause*. 2000;7(3):156–61.
181. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. *Arch Ophthalmol*. 1992;110(12):1701–8.
182. Risks and benefits estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288(3):321–33.
183. Rosano G, Vitale C, Spoletini I, Fini M. Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy. *Climacteric*. 2012;15(4):299–305.
184. Rosano GMC, Mercurio G, Vitale C, et al. How progestins influence the cardiovascular effect of hormone replacement therapy. *Gynecol Endocrinol*. 2001;15 Suppl 6:9–17.
185. Rosati D, Miheli S, Pinto S, et al. Changes in lipidic and hemostatic parameters induced by tibolone treatment. *Thromb Res*. 1997; 85(3):273–8.
186. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. *J Natl Cancer Instit*. 2000;92:485–91.
187. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA*. 2007;297(13):1465–77. Erratum in: *JAMA*. 2008;299(12):1426.

188. Salmon UJ, Walter RI, Gerst SH. The use of estrogen in the treatment of dysurie et incontinence in postmenopausal women. *Amer J Obstet Gynec.* 1941;42:845–9.
189. Salpeter SR, Walsh JM., Greyber E., et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. *J Gen Intern Med.* 2004;19(7):791–804.
190. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. *J Gen Intern Med.* 2006 Apr;21(4):363–6. Erratum in: *J Gen Intern Med.* 2008;23(10):1728.
191. Salvatore S, Leone RMU, Athanasiou S et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. *Menopause.* 2015;22(8):845–9.
192. Samsioe G et al. *Menopause.* 1998;5(4):259b.
193. Sánchez-Guerrero J, Liang MH, Karslon EW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. *Ann Intern Med.* 1995;122(6):430–3.
194. Sannten RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. *J Clin Endocrinol Metab.* 2010; 95(7 Suppl 1):s1–s66.
195. Seed M, Knopp RH. Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebo-controlled trials of hormone-replacement therapy. *Curr Opin Lipidol.* 2004;15(4):459–67.
196. Shlipak MG, Angeja BG, Go AS et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. *Circulation.* 2001;104(19):2300–4.
197. Shlipak MG, Angeja BG, Go AS, et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. *Circulation.* 2001;104(19):2300–4.
198. Schairer C, Lubin J, Troisi R et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA.* 2000;283(4):485–91.
199. Schaumberg DA, Burington JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. *JAMA.* 2001;286(17): 2114–9.
200. Siliquini GP, Tuninetti V, Bournous VE et al. Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women. *Climacteric.* 2017;20(4):379–84.
201. Simunić V, Banović I, Ciglar S, et al. Local estrogen treatment in patient with urogenital symptoms. *Int J Gynaecol Obstet.* 2003;82(2):187–97.
202. Simunić V, Banović I, Ciglar S et al. Local estrogen treatment in patients with urogenital symptoms. *Int J Gynaecol Obstet.* 2003; 82(2):187–97.
203. Slattery ML, Ballard-Bardash R, Edward S et al. Body mass index and colon cancer. *Cancer Causes Control.* 2003;14(1):75–84.
204. Spector TD, Nandra D, Hart DJ, Doyle DV. Is hormone replacement therapy protective for hand and knee osteoarthritis in women? The Chingford Study. *Ann Rheum Dis.* 1997;56(7):432–4.
205. Speroff L, Fritz MA. *Clinical Gynecologic Endocrinology and Infertility.* Philadelphia: Williams and Wilkins; 7th edition; 2005.

206. Stevenson JC, Durand G, Kahler E, Pertynski T. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17 β -oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. *Maturitas*. 2010;67(3):227–32.
207. Stevenson JC. Justification for the use of HRT in the long-term prevention of osteoporosis. *Maturitas*. 2005;51(2):113–26.
208. Strnad P. Nemoci prsu v každodenní praxi. Praha: Maxdorf; 2014.
209. Sturdee DW, Archer DF, Rakov V, Lang E. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. *Climacteric*. 2008; 11(1):63–73.
210. Štěpán J, Payer J, Abrahámová J. Stratifikace léčby postmenopauzální osteoporózy. *Prakt Lek*. 2004;84(9):500–6.
211. Tankó LB, Søndergaard BC, Oestergaard S, et al. An update review of cellular mechanisms conferring the indirect and direct effects of estrogen on articular cartilage. *Climacteric*. 2008;11(1):4–16.
212. The 2017 Hormone Therapy Position Statement of The North American Menopause Society. *Menopause* 2017, 24: 728-53
213. Tchernof A, Desmeules A, Richard C, et al. Ovarian hormone status and abdominal visceral adipose tissue metabolism. *J Clin Endocrinol Metab*. 2004;89(7):3425–30.
214. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. *JAMA*. 2001;285(22):2891–7.
215. Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. *Am J Respir Crit Care Med*. 1995;152(4 Pt 1):1183–8.
216. Ulrich LS, Naessen T, Elia D, et al. Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. *Climacteric*. 2010;13(3):228–37.
217. Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double blind, placebo-controlled study. *Fertil Steril*. 2004;82(1):145–8, quiz 265.
218. Utian WH, Archer DF, Bachmann GA. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. *Menopause*. 2008;15(4):584–602.
219. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. *Fertil Steril*. 2001;75(6):1065–79.
220. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. *Clin Drug Investig*. 2000;20(2):101–7.
221. Van de Mooren MJ. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. *Eur J Clin Invest*. 1994;24(11):733–6.
222. Van Wersch JW, Ubachs JM, van den Ende A, et al. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women. *Eur J Clin Chem Clin Biochem*. 1994;32(6):449–453.

223. Vingerling JR, Dielemans I, Witteman JCM et al. Macular degeneration and early menopause: a case control study. *Br Med J*. 1995; 310:1570–1.
224. Visser M, Coelligh Bennink HJ. Clinical application for estetrol. *J Steroid Biochem Mol Biol*. 2009;114(1–2):85–9.
225. Von Eckardstein A, Schmiedem K, Hövels A. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. *Atherosclerosis*. 2001;159(2):433–9.
226. Von Mühlen D, Morton D, Von Mühlen CA, et al. Postmenopausal estrogen and increased risk of clinical osteoarthritis at the hip, hand, and knee in older women. *J Womens Health Gend Based Med*. 2002;11(6):511–8.
227. Walitt B, Pettinger M, Weinstein A, et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: the women's health initiative randomized controlled trials. *Arthritis Rheum*. 2008;59(3): 302–10.
228. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. *J Clin Endocrinol Metab*. 2000;85(1):214–8.
229. Waters DD, Alderman EL, Hsia A, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. *JAMA*. 2002;288(19):2432–40.
230. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocr Rev*. 2002;23(4):529–39.
231. Whitehead M. The prescriber's guide to hormone replacement therapy. New York: Parthenon Publishing; 1998.
232. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coeligh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. *Fertil Steril*. 2000;74(1):10–9.
233. Wu-Wiliams AH, Lee M, Whittemore AS et al. Reproductive factors and colorectal cancer risk among Chinese females. *Cancer Res*. 1991;51:2307–1.
234. Zhang Y, McAlindon TE, Hannan MT, et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. *Arthritis Rheum*. 1998;41(10):1867–73.
235. Zhengguang Ch, Molykutty J, Saradha S et al. 17beta-estradiol confers a protective effect against transforming growth factor-beta2-induced cataract in female but not male lenses. *Exp. Eye Research*. 2004;78:67–74.
236. Zhu W, Everson WV, Smart E. Estrogen in cardiovascular disease. *Curr Opin Lipidol*. 2004;15(5):589–93.
237. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. *N Engl J Med*. 1975;293(23):1167–70.